Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

with advanced prostate cancer, many patients will eventually develop treatment resistance and their disease will progress."

Cormack added, "Our partnership with Teva Pharmaceuticals has financed a robust clinical trial program for custirsen and provided us with the cash to fund operations into mid-2012, while retaining royalty rates which we estimate at the higher tiers could approach economics seen in profit-sharing arrangements. We're now focusing on advancing OGX-427 to more fully realize its diverse potential. We are currently evaluating various alternatives, including partnering, which would allow us to expand the OGX-427 development plan beyond the ongoing Phase 1 bladder cancer trial and the randomized Phase 2 prostate cancer trial planned to initiate later this year."

Recent Accomplishments and Anticipated Milestones

    Custirsen
    ---------

      -  In partnership with Teva, we initiated the international Phase 3
         Prostate Cancer SATURN trial evaluating custirsen with docetaxel
         retreatment as second-line therapy in castrate-resistant prostate
         cancer (CRPC). The SATURN trial will be conducted in approximately
         50 cancer centers and will enroll approximately 300 men who have
         previously responded to first-line docetaxel therapy, but
         subsequently have disease progression that involves prostate cancer-
         related pain despite opioid usage.

      -  Two additional Phase 3 trials will be initiated evaluating custirsen
         in first-line treatment of metastatic CRPC and first-line treatment
         of advanced, unresectable non-small cell lung cancer (NSCLC). Both
         trials will be in combination with chemotherapy and will assess
         overall survival as the primary endpoint.

    OGX-427
    -------

      -  Final results from a Phase 1 trial of OGX-427 were announced at the
         ASCO 2010 Annual Meetin
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Medical, Inc., a medical device,company that has developed ... aneurysms, announced today that they have successfully raised ... Valor,s Chief,Executive Officer, Clark Adams stated, "Valor,s Board ... that will be used to complete,clinical trials needed ...
... 6 NutraCea (OTC Bulletin Board:,NTRZ), a world ... and,technology announced today that it has appointed Olga ... Todd Crow, in accordance with,his previously announced intentions, ... a consulting and advisory capacity., Ms. Hernandez-Longan ...
... loss narrows on higher revenue due to Roche milestone -, ... ) today announced results from operations for the third,quarter and ... for the third quarter of 2008 of $12.5 million, or ... or $0.66 per share, in the third,quarter of 2007., ...
Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 8InterMune Reports Third Quarter 2008 Financial Results and Business Highlights 9
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Society for Microbiology (ASM) ICAAC Young Investigator Award ... University of Minnesota, Minneapolis. Sponsored by Merck U.S. ... for research excellence in microbiology and infectious diseases. ... the immunological memory of bacterial and viral pathogens ...
... Ohio -- Engineers at Ohio State University have found a ... might someday replace gasoline in automobiles. The process improves ... fermentation tank. Normally, bacteria could only produce a certain ... for every liter of water in the tank -- before ...
... Blacksburg, Va. -- After engineers and scientists at Virginia Tech, ... water, Michael Phelps may find he still has a few ... ,The remarkable ability of fish to maneuver in ... to accelerate in a seemingly effortless fashion has researchers wondering ...
Cached Biology News:Researchers boost production of biofuel that could replace gasoline 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 2NSF Emerging Frontiers' program supports development of smart materials based on study of fish 3
... Microplate Luminometer has been designed,for the ... for,all measurements of glow and flash ... the light remain nearly constant,over a ... as for very fast reactions,requiring at ...
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... Plasmid-Based Deletion Machine is based on the ... developed by Goryshin and Reznikoff, and by ... families of deletions and inversions by intramolecular ... transposon-containing plasmid vector. Although most researchers will ...
... knockout or alter genes on the E.coli ... recombination allows the exchange of genetic information in ... An FRT-flanked kanamycin resistance marker cassette is supplied ... replace a gene on the E.coli ...
Biology Products: